{"type":"trials","record":{"id":41969,"source_id":"clinicaltrials-gov","external_id":"NCT05403749","title":"A Study of Longer Interval of IVT IBI302 in Subjects With nAMD","brief_summary":"The study is designed for multi-center, randomized, double-masked, active-controlled study to evaluate the longer interval of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrollment":132,"countries":["China"],"start_date":"2022-06-29","completion_date":"2024-05-13","last_update_date":"2024-06-28","source_url":"https://clinicaltrials.gov/study/NCT05403749","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Aflibercept","organization":"Innovent Biologics (Suzhou) Co. Ltd.","interventions":["dose 1 IBI302","Aflibercept","dose 2 IBI302"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change of BCVA from baseline — Baseline to week 40","Percentage of Participants Loss >0,≥5,10，15 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline to wee…","Change of Central Subfield Thickness in the Study Eye from baseline — Baseline to week 52","Change of Total Area of Choroidal Neovascularization (CNV) Lesion/Total Area of Choroidal Neovascularization Leakage in…","Percentage of Participants in different dosage of IBI302 Arm on Once Every 8-Weeks, 12-Weeks,Treatment Intervals — At W…","Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants…","Percentage of Participants Gaining ≥0,5,10,15 Letters From the Baseline BCVA in the Study Eye Over Time — From Baseline…","Immunogenicity end points — From Baseline to week 52"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","dose 1 IBI302","Aflibercept","dose 2 IBI302"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05403749","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-06-29 to 2024-05-13","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.901Z","intervention":["dose 1 IBI302","Aflibercept","dose 2 IBI302"],"participants":132,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change of BCVA from baseline — Baseline to week 40","Percentage of Participants Loss >0,≥5,10，15 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline to wee…","Change of Central Subfield Thickness in the Study Eye from baseline — Baseline to week 52","Change of Total Area of Choroidal Neovascularization (CNV) Lesion/Total Area of Choroidal Neovascularization Leakage in…","Percentage of Participants in different dosage of IBI302 Arm on Once Every 8-Weeks, 12-Weeks,Treatment Intervals — At W…","Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants…","Percentage of Participants Gaining ≥0,5,10,15 Letters From the Baseline BCVA in the Study Eye Over Time — From Baseline…","Immunogenicity end points — From Baseline to week 52"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41969","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}